Sugi Predict

Sugi Predict / Compounds / SCHEMBL3712422

SCHEMBL3712422

SCHEMBL3712422

CC(Cl)C(=O)N1CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ PKM P14618 1/20 0.50
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ GAA P10253 3/20 0.47
▸ HPGD P15428 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ TSHR P16473 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ TP53 P04637 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ MMP1 P03956 1/20 0.42
▸ MMP3 P08254 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6332947 1.00 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL6330365 1.00 ALDH1A1 (0.57) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL7350726 0.92 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL19092009 0.89 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL6933685 0.84 ALDH1A1 (0.68) ALDH1A1KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL11846880 0.84 — —
SCHEMBL8395805 0.83 SMN1; SMN2 (0.50) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL738198 0.82 SMN1; SMN2 (0.54) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL11349694 0.82 MMP1 (0.50) ALDH1A1KMT2AMEN1SMN1; SMN2PKM
SCHEMBL762984 0.80 SMN1; SMN2 (0.52) ALDH1A1KMT2AMEN1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230097700-A1 AZETIDINE SULFONAMIDE COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-30 — — US disclosed
EP-4082611-A1 AZETIDINE SULFONAMIDE COMPOUND Daiichi Sankyo Company, Limited (JP) 2022-11-02 — — EP disclosed
CN-108884029-B LSD1 inhibitors 米拉蒂医疗股份有限公司 2021-10-26 — — CN disclosed
WO-2021112251-A1 AZETIDINE SULFONAMIDE COMPOUND 第一三共株式会社 2021-06-10 — — WO disclosed
EP-3397616-B1 LSD1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2020-06-10 — — EP disclosed
EP-3397616-B1 LSD1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2020-06-10 — — EP disclosed
US-10233152-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2019-03-19 — — US disclosed
US-10233152-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2019-03-19 — — US disclosed
EP-3397616-A1 LSD1 INHIBITORS Mirati Therapeutics, Inc. (US) 2018-11-07 — — EP disclosed
US-20180127369-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. 2018-05-10 — — US disclosed
US-9809541-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2017-11-07 — — US disclosed
US-9809541-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2017-11-07 — — US disclosed
WO-2017116558-A1 LSD1 INHIBITORS Mirati Therapeutics, Inc. (US) 2017-07-06 — — WO disclosed
US-20170183308-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. (US) 2017-06-29 — — US disclosed
US-20170183308-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. (US) 2017-06-29 — — US disclosed
US-20170183308-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. (US) 2017-06-29 — — US disclosed
US-20120122843-A1 Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases ASTRAZENECA AB (SE) 2012-05-17 — — US disclosed
US-6916927-B2 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction PFIZER INC. 2005-07-12 — — US disclosed
US-20040180944-A1 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction PFIZER INC 2004-09-16 — — US disclosed
US-6723719-B1 DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS PFIZER INC 2004-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180944-A1 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction PDE5A, PDE3A, PDE3B ALDH1A1 266/4885KMT2A 4191/4885MEN1 4470/4885
US-10233152-B2 LSD1 inhibitors KDM1B, KDM1A, KDM3A ALDH1A1 364/4885KMT2A 29/4885MEN1 3225/4885
US-20170183308-A1 LSD1 Inhibitors KDM1B, KDM1A, KDM3A ALDH1A1 364/4885KMT2A 29/4885MEN1 3225/4885
US-20120122843-A1 Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases APP, BACE1, PSEN1 ALDH1A1 2363/4885KMT2A 4647/4885MEN1 421/4885
US-20180127369-A1 LSD1 Inhibitors KDM1B, KDM1A, KDM3A ALDH1A1 364/4885KMT2A 29/4885MEN1 3225/4885
US-20230097700-A1 AZETIDINE SULFONAMIDE COMPOUND IFNG, IFNAR1, STAT1 ALDH1A1 1320/4885KMT2A 788/4885MEN1 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.